patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_422628 | REC_0017801 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 2.2 | 54 | male | 0 | 33 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.4 | false | MSS | 2026-03-15T05:36:02.705322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723813 | REC_0017802 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.5 | 58 | male | 0 | 32 | 6.3 | 4 | osimertinib 80 mg daily | 17.8 | true | MSS | 2026-03-15T05:36:02.706163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592795 | REC_0017803 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 16 | 62 | female | 1 | 15 | 5.2 | 2 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:36:02.706977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590067 | REC_0017804 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.5 | 63 | female | 1 | 10 | 6.9 | 1 | entrectinib 600 mg daily | 22.5 | false | MSS | 2026-03-15T05:36:02.707804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794382 | REC_0017805 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.2 | 59 | female | 0 | 17 | 5.3 | 5 | osimertinib 80 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:36:02.708710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483772 | REC_0017806 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.6 | 56 | female | 1 | 14 | 6.1 | 6 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:36:02.709528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729916 | REC_0017807 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.2 | 69 | female | 1 | 10 | 5.9 | 1 | entrectinib 600 mg daily | 30.4 | false | MSI-H | 2026-03-15T05:36:02.710268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114946 | REC_0017808 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12 | 66 | female | 1 | 13 | 6.6 | 2 | osimertinib 80 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:02.711038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638430 | REC_0017809 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.8 | 62 | female | 1 | 27 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.7 | true | MSS | 2026-03-15T05:36:02.711853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197080 | REC_0017810 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.1 | 75 | female | 2 | 9 | 5 | 5 | osimertinib 80 mg daily | 12 | false | MSI-H | 2026-03-15T05:36:02.713307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471605 | REC_0017811 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 24 | 14.9 | 81 | female | 2 | 7 | 5.9 | 0 | alectinib 600 mg BID | 36.9 | false | MSS | 2026-03-15T05:36:02.715001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788589 | REC_0017812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.4 | 74 | female | 1 | 21 | 5.5 | 1 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:02.715892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218461 | REC_0017813 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 6.3 | 62 | female | 0 | 17 | 3.2 | 5 | entrectinib 600 mg daily | 18.8 | true | MSS | 2026-03-15T05:36:02.716886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284072 | REC_0017814 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 19.3 | 78 | female | 1 | 5 | 7.1 | 2 | osimertinib 80 mg daily | 22.2 | false | MSI-H | 2026-03-15T05:36:02.717822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381732 | REC_0017815 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.9 | 63 | female | 1 | 47 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.4 | true | MSS | 2026-03-15T05:36:02.718680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461982 | REC_0017816 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 5 | 74 | female | 2 | 10 | 5.9 | 0 | osimertinib 80 mg daily | 63.1 | true | MSS | 2026-03-15T05:36:02.719533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978004 | REC_0017817 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 10.7 | 63 | female | 0 | 21 | 4.2 | 1 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:36:02.720429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623279 | REC_0017818 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.4 | 58 | male | 1 | 10 | 5.9 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.721301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314327 | REC_0017819 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.3 | 68 | female | 0 | 2 | 4.5 | 4 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:02.722319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734338 | REC_0017820 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9 | 79 | female | 1 | 18 | 5.7 | 7 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.723333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113671 | REC_0017821 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10.3 | 75 | female | 1 | 7 | 7.4 | 2 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:36:02.724495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413611 | REC_0017822 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 12.2 | 68 | female | 0 | 0 | 4.2 | 1 | entrectinib 600 mg daily | 22.4 | true | MSI-H | 2026-03-15T05:36:02.725472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939903 | REC_0017823 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 12 | 12.4 | 60 | male | 1 | 27 | 7.9 | 1 | sotorasib 960 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:36:02.726446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135099 | REC_0017824 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.6 | 72 | female | 2 | 11 | 6 | 9 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:36:02.727762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329156 | REC_0017825 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 18.7 | 70 | female | 1 | 8 | 6.8 | 1 | entrectinib 600 mg daily | 19.4 | true | MSI-H | 2026-03-15T05:36:02.729322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294988 | REC_0017826 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.3 | 69 | female | 1 | 18 | 7.6 | 2 | sotorasib 960 mg daily | 25.5 | false | MSS | 2026-03-15T05:36:02.730217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659285 | REC_0017827 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.5 | 76 | female | 3 | 27 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:36:02.731044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387241 | REC_0017828 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.7 | 65 | female | 0 | 44 | 7.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 14.2 | false | MSS | 2026-03-15T05:36:02.731918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609256 | REC_0017829 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.8 | 66 | male | 0 | 58 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:36:02.733187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568828 | REC_0017830 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 7.8 | 72 | female | 2 | 15 | 6.3 | 0 | alectinib 600 mg BID | 41.3 | false | MSS | 2026-03-15T05:36:02.734055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702139 | REC_0017831 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 17.2 | 55 | male | 0 | 19 | 4.6 | 9 | sotorasib 960 mg daily | 10 | false | MSI-H | 2026-03-15T05:36:02.734965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321426 | REC_0017832 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.6 | 67 | female | 0 | 14 | 3.6 | 6 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:36:02.735895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253855 | REC_0017833 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.2 | 60 | female | 1 | 42 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.6 | false | MSS | 2026-03-15T05:36:02.737008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288851 | REC_0017834 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 3.4 | 73 | female | 0 | 12 | 5.7 | 2 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:36:02.738107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399473 | REC_0017835 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.6 | 64 | female | 0 | 17 | 5.4 | 1 | alectinib 600 mg BID | 26.2 | true | MSS | 2026-03-15T05:36:02.739027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696286 | REC_0017836 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 12.6 | 60 | male | 0 | 7 | 7.1 | 4 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:36:02.739902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649813 | REC_0017837 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.6 | 70 | male | 1 | 30 | 7.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:36:02.741186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829380 | REC_0017838 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 11.8 | 72 | female | 0 | 14 | 3.3 | 2 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:02.742074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796954 | REC_0017839 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 4.2 | 65 | female | 1 | 56 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:36:02.742876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373915 | REC_0017840 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 5.8 | 62 | female | 1 | 6 | 5.1 | 9 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:36:02.743656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478474 | REC_0017841 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 34 | 17.2 | 71 | female | 2 | 23 | 3.8 | 0 | pembrolizumab 200 mg q3w | 14.9 | true | MSI-H | 2026-03-15T05:36:02.744606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407023 | REC_0017842 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.6 | 65 | female | 0 | 45 | 4 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:36:02.745417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567023 | REC_0017843 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.1 | 67 | female | 0 | 42 | 4.1 | 7 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:36:02.746226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939291 | REC_0017844 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.6 | 60 | male | 0 | 48 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.4 | true | MSS | 2026-03-15T05:36:02.747051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697248 | REC_0017845 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.2 | 66 | male | 1 | 59 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:36:02.747924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393498 | REC_0017846 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 20.7 | 55 | female | 1 | 8 | 6.4 | 5 | sotorasib 960 mg daily | 5.4 | true | MSI-H | 2026-03-15T05:36:02.748975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845733 | REC_0017847 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 15.6 | 69 | female | 1 | 11 | 2.6 | 4 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:02.750436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403113 | REC_0017848 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.4 | 65 | male | 1 | 15 | 5 | 5 | alectinib 600 mg BID | 6.1 | false | MSI-H | 2026-03-15T05:36:02.751452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256300 | REC_0017849 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.2 | 70 | female | 1 | 85 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.6 | true | MSS | 2026-03-15T05:36:02.752616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945456 | REC_0017850 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.1 | 54 | female | 0 | 13 | 3.9 | 2 | alectinib 600 mg BID | 18 | true | MSI-H | 2026-03-15T05:36:02.753984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931649 | REC_0017851 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 3.6 | 78 | male | 1 | 11 | 4.1 | 6 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:02.754846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265346 | REC_0017852 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 21 | 52 | female | 0 | 14 | 5.3 | 2 | osimertinib 80 mg daily | 26.2 | false | MSI-H | 2026-03-15T05:36:02.755706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296444 | REC_0017853 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12 | 75 | female | 2 | 16 | 3.7 | 2 | sotorasib 960 mg daily | 19 | true | MSS | 2026-03-15T05:36:02.756794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462111 | REC_0017854 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 15.2 | 63 | female | 0 | 15 | 6.1 | 4 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:36:02.757699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281548 | REC_0017855 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.2 | 66 | female | 1 | 34 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.9 | true | MSS | 2026-03-15T05:36:02.758498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860667 | REC_0017856 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 5.5 | 63 | male | 1 | 20 | 5.8 | 5 | alectinib 600 mg BID | 11.2 | true | MSS | 2026-03-15T05:36:02.759298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270805 | REC_0017857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.7 | 60 | female | 0 | 21 | 5.2 | 7 | alectinib 600 mg BID | 15.5 | true | MSI-H | 2026-03-15T05:36:02.760353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592173 | REC_0017858 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 13.8 | 63 | female | 0 | 9 | 6.2 | 2 | osimertinib 80 mg daily | 18.5 | false | MSS | 2026-03-15T05:36:02.761175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207681 | REC_0017859 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.1 | 69 | female | 0 | 1 | 5.6 | 4 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:36:02.761993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200798 | REC_0017860 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13 | 67 | female | 0 | 13 | 7.1 | 8 | sotorasib 960 mg daily | 13 | true | MSS | 2026-03-15T05:36:02.762784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861938 | REC_0017861 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 5.8 | 73 | female | 2 | 22 | 5.6 | 4 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:02.763560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176864 | REC_0017862 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.6 | 90 | female | 1 | 15 | 5.2 | 3 | alectinib 600 mg BID | 7.5 | false | MSS | 2026-03-15T05:36:02.764533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411069 | REC_0017863 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 10.9 | 71 | female | 2 | 65 | 6.7 | 8 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:36:02.765627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398086 | REC_0017864 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 15.6 | 74 | female | 1 | 12 | 4.2 | 6 | pembrolizumab 200 mg q3w | 14.8 | false | MSI-H | 2026-03-15T05:36:02.766456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528732 | REC_0017865 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 18.9 | 66 | female | 1 | 15 | 6 | 5 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:36:02.767264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738813 | REC_0017866 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 17.3 | 79 | female | 2 | 3 | 7.1 | 3 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:36:02.768231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468162 | REC_0017867 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 10.3 | 76 | female | 2 | 6 | 6.1 | 7 | entrectinib 600 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:02.769165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154601 | REC_0017868 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 3 | 75 | female | 2 | 31 | 8.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.4 | false | MSS | 2026-03-15T05:36:02.770042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275114 | REC_0017869 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 15.1 | 61 | female | 1 | 23 | 5.2 | 8 | sotorasib 960 mg daily | 14.2 | false | MSS | 2026-03-15T05:36:02.770866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315030 | REC_0017870 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 16.2 | 77 | female | 3 | 7 | 6.4 | 1 | pembrolizumab 200 mg q3w | 22.9 | false | MSI-H | 2026-03-15T05:36:02.771714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245201 | REC_0017871 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 16.8 | 61 | male | 0 | 22 | 5.5 | 4 | alectinib 600 mg BID | 9.6 | true | MSI-H | 2026-03-15T05:36:02.772638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948929 | REC_0017872 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 10.4 | 71 | female | 1 | 17 | 4.9 | 2 | osimertinib 80 mg daily | 26.1 | true | MSS | 2026-03-15T05:36:02.773438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893601 | REC_0017873 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 13.4 | 71 | female | 3 | 11 | 4.2 | 4 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:36:02.774229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976090 | REC_0017874 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.4 | 69 | female | 0 | 29 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.3 | true | MSS | 2026-03-15T05:36:02.775494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949848 | REC_0017875 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.6 | 59 | male | 1 | 32 | 3.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.5 | true | MSS | 2026-03-15T05:36:02.776521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417605 | REC_0017876 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 6.4 | 60 | male | 0 | 15 | 6.9 | 2 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:36:02.777865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377748 | REC_0017877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 4.1 | 62 | female | 1 | 10 | 4.9 | 7 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:02.778867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516511 | REC_0017878 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 16.6 | 53 | male | 0 | 13 | 6.9 | 1 | osimertinib 80 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:36:02.779774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894027 | REC_0017879 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 17.2 | 74 | female | 1 | 12 | 5.8 | 1 | alectinib 600 mg BID | 22.5 | true | MSS | 2026-03-15T05:36:02.780644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133683 | REC_0017880 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.6 | 83 | female | 2 | 28 | 4.9 | 5 | pembrolizumab 200 mg q3w | 11.1 | true | MSS | 2026-03-15T05:36:02.781568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968228 | REC_0017881 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 14.5 | 64 | male | 1 | 7 | 6 | 1 | entrectinib 600 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:36:02.782671+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832794 | REC_0017882 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 16.1 | 51 | male | 0 | 15 | 6.4 | 4 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:02.783414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406669 | REC_0017883 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.6 | 74 | female | 2 | 13 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:36:02.784344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470629 | REC_0017884 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.7 | 69 | female | 0 | 20 | 5.1 | 5 | osimertinib 80 mg daily | 5.2 | true | MSS | 2026-03-15T05:36:02.785942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798633 | REC_0017885 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7 | 61 | male | 0 | 54 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:36:02.786973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165737 | REC_0017886 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.4 | 74 | female | 2 | 7 | 3.3 | 1 | entrectinib 600 mg daily | 21.6 | false | MSI-H | 2026-03-15T05:36:02.789002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702103 | REC_0017887 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 30 | 12.2 | 72 | male | 0 | 6 | 5 | 0 | pembrolizumab 200 mg q3w | 47.9 | false | MSI-H | 2026-03-15T05:36:02.790095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910715 | REC_0017888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13.2 | 77 | female | 1 | 7 | 3.6 | 4 | osimertinib 80 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:36:02.790807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585055 | REC_0017889 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 5.5 | 69 | male | 0 | 19 | 4.8 | 2 | sotorasib 960 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:02.791684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991353 | REC_0017890 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 15.9 | 71 | female | 2 | 5 | 5.4 | 2 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:36:02.792516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867243 | REC_0017891 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.3 | 88 | female | 1 | 43 | 6.4 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:02.793296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420576 | REC_0017892 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 4.6 | 59 | female | 0 | 48 | 7.5 | 1 | pembrolizumab 200 mg q3w | 25.7 | true | MSS | 2026-03-15T05:36:02.794079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821622 | REC_0017893 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12 | 64 | male | 1 | 13 | 5.3 | 7 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:02.794906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745947 | REC_0017894 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.3 | 69 | female | 1 | 54 | 3 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:36:02.795684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864809 | REC_0017895 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.2 | 74 | female | 1 | 17 | 6.2 | 2 | sotorasib 960 mg daily | 16.2 | false | MSI-H | 2026-03-15T05:36:02.796658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297272 | REC_0017896 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12 | 66 | female | 1 | 17 | 6.3 | 2 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:36:02.797598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525629 | REC_0017897 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 12.8 | 71 | female | 3 | 16 | 4.6 | 1 | entrectinib 600 mg daily | 18.1 | true | MSS | 2026-03-15T05:36:02.798456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400254 | REC_0017898 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 6.3 | 75 | female | 2 | 18 | 5.3 | 1 | osimertinib 80 mg daily | 25.1 | true | MSS | 2026-03-15T05:36:02.799303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904796 | REC_0017899 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 9.6 | 63 | female | 0 | 8 | 5.3 | 3 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:02.800027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352343 | REC_0017900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 9.5 | 71 | male | 2 | 8 | 4.4 | 4 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:36:02.800798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.